Ligand Pharmaceuticals - LGND Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ligand Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" LGND shares.
View LGND analyst ratings or view top-rated stocks.

4 equities research analysts have issued 1-year price targets for Ligand Pharmaceuticals' stock. Their LGND share price forecasts range from $90.00 to $160.00. On average, they anticipate the company's stock price to reach $119.00 in the next twelve months. This suggests a possible upside of 67.7% from the stock's current price.
View analysts price targets for LGND or view top-rated stocks among Wall Street analysts.

Ligand Pharmaceuticals' stock was trading at $66.80 at the beginning of 2023. Since then, LGND stock has increased by 6.2% and is now trading at $70.96.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 16th 2023.
View our LGND earnings forecast.

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) released its quarterly earnings data on Monday, November, 7th. The biotechnology company reported ($0.20) EPS for the quarter, missing analysts' consensus estimates of $0.09 by $0.29. The biotechnology company earned $66.09 million during the quarter, compared to analysts' expectations of $38.47 million. Ligand Pharmaceuticals had a negative net margin of 8.62% and a positive trailing twelve-month return on equity of 2.57%.

Ligand Pharmaceuticals updated its FY 2022 earnings guidance on Wednesday, December, 21st. The company provided earnings per share (EPS) guidance of $4.30-$4.45 for the period, compared to the consensus EPS estimate of $4.24. The company issued revenue guidance of $184.00 million-$189.00 million, compared to the consensus revenue estimate of $212.82 million.

1 employees have rated Ligand Pharmaceuticals Chief Executive Officer John L. Higgins on Glassdoor.com. John L. Higgins has an approval rating of 100% among the company's employees. This puts John L. Higgins in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ligand Pharmaceuticals investors own include Jazz Pharmaceuticals (JAZZ), Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), AbbVie (ABBV), Netflix (NFLX), Cisco Systems (CSCO), Illumina (ILMN) and Gilead Sciences (GILD).

Ligand Pharmaceuticals trades on the NASDAQ under the ticker symbol "LGND."

Ligand Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Villere ST Denis J & Co. LLC (2.86%), Stephens Investment Management Group LLC (2.69%), Chicago Capital LLC (1.89%), Woodstock Corp (0.33%), Allspring Global Investments Holdings LLC (0.17%) and AMI Asset Management Corp (0.12%). Insiders that own company stock include Charles S Berkman, John L Higgins, John W Kozarich, Matthew W Foehr, Octavio Espinoza and Todd C Davis.
View institutional ownership trends.

Shares of LGND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of LGND stock can currently be purchased for approximately $70.96.

Ligand Pharmaceuticals (NASDAQ:LGND) has a market capitalization of $1.20 billion and generates $277.13 million in revenue each year. The biotechnology company earns $57.14 million in net income (profit) each year or ($1.24) on an earnings per share basis.

The company employs 154 workers across the globe.

Ligand Pharmaceuticals' mailing address is 3911 SORRENTO VALLEY BLVD SUITE 110, SAN DIEGO CA, 92121. The official website for the company is www.ligand.com. The biotechnology company can be reached via phone at (858) 550-7500, via email at investors@ligand.com, or via fax at 858-550-1826.